The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictors of long-term responders in patients treated with pazopanib for advanced renal cell carcinoma (aRCC).
 
Jinhee Park
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Research Funding - Novartis
Travel, Accommodations, Expenses - Novartis
 
Xiaolong Jiao
Employment - McKesson
Research Funding - Novartis (Inst)
 
Thomas Wilson
Employment - McKesson
Leadership - Trajectory Healthcare
Stock and Other Ownership Interests - Trajectory Healthcare
Patents, Royalties, Other Intellectual Property - Trajectory Healthcare
 
Sameer Ghate
Employment - Novartis
Stock and Other Ownership Interests - Exelixis (I)
Travel, Accommodations, Expenses - Novartis
 
Qasim Ahmad
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Travel, Accommodations, Expenses - Novartis
Other Relationship - Novartis
 
Jose Ricardo Perez
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Dendreon; Endocyte; Janssen Oncology; Mannkind; Pfizer; UpToDate
Consulting or Advisory Role - Amgen; AVEO; Bayer; BIND Biosciences; Cerulean Pharma; Churchill Pharmaceuticals; Genentech/Roche; HERON; Janssen Biotech; Labceutics; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Caris MPI; Dendreon; Genentech/Roche; GlaxoSmithKline; Medivation; Millennium; Pfizer; Sanofi
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology